Research Radartracking 1,316 published studies · 343 human · 8 safety signals · 43 clinical trials · 44 cancer pages · updated Aug 2026Open the Research Map →
← Back to Ovarian Carcinosarcoma

Appointment dossier — Ovarian Carcinosarcoma

Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.

Compounds studied in Ovarian Carcinosarcoma

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Guideline-backed standard of care

Primary cytoreductive surgery, Goal: complete or optimal cytoreduction (<1 cm residual disease), as residual tumor volume, Hysterectomy with bilateral salpingo-oophorectomy and omentectomy, In advanced disease, radical debulking (bowel resection, splenectomy, diaphragm stripping), Interval debulking (surgery after initial chemotherapy), Fertility-sparing surgery, Not routinely used in frontline management, but, Pelvic or para-aortic radiation, Stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT), Radiation, Use cautiously in heavily pre-treated patients due to marrow reserve and bowel tolerance, Platinum/taxane doublet (e.g., carboplatin + paclitaxel), Response rates, Ifosfamide/doxorubicin or gemcitabine/docetaxel regimens, PARP inhibitors (e.g., olaparib, niraparib), Immunotherapy (PD-1/PD-L1 inhibitors), Bevacizumab (anti-VEGF) has been used in select cases; timing around surgery and wound healing, Clinical trial enrollment, Platinum/Taxane (epithelial-leaning), Ifosfamide/Doxorubicin variants (sarcomatous-leaning), Gemcitabine/Docetaxel (sarcoma option) (recurrent/palliative), PARP inhibitor maintenance (contextual) (BRCA/HRD-positive), MSI-high, dMMR, or TMB-high tumors: these subsets, PD-1/PD-L1 expression: variable across OCS, HER2 overexpression/amplification: uncommon but actionable, EGFR and related receptor tyrosine kinases: occasionally expressed in carcinosarcomas. Small-molecule inhibitors have shown activity in other tumors, but OCS data, VEGF/angiogenesis signaling: bevacizumab has been incorporated in some regimens for epithelial ovarian cancer and has been tried in OCS. Benefits.

The established options for Ovarian Carcinosarcoma — ask which apply to your case. Investigational options appear in the compounds list above.

Open recruiting trials (18)

Most-relevant first: trials that name Ovarian Carcinosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Interactions & safety to discuss

Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.

Financial help to look into

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

  1. Has my tumor been tested for p53, and would the result open up targeted treatments or trials?
  2. Has my tumor been tested for ER/PR, and would the result open up targeted treatments or trials?
  3. Has my tumor been tested for BRCA1/2 / HRD, and would the result open up targeted treatments or trials?
  4. I've read that Paclitaxel has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
  5. I've read that Carboplatin has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
  6. I've read that Ifosfamide has been studied in people for Ovarian Carcinosarcoma — what's the evidence, and is it an option or available in a trial for me?
  7. Of the open trials I found (for example NCT03651206), am I eligible for any — here or at a larger cancer center?
  8. Is my tumor epithelial-dominant, sarcoma-dominant, or truly mixed — and how does that affect treatment options?
  9. How aggressive is my specific case based on stage, grade, and pathology markers?
  10. What is my likely prognosis, and how do factors like BRCA/HRD or complete cytoreduction influence survival?
  11. Can cytoreductive surgery be complete (R0) or optimal in my case, and what risks are involved?
  12. Should I seek surgery at a high-volume center experienced in ovarian carcinosarcoma?
  13. If surgery is not possible, what other disease-control strategies are available?
  14. If chemo is planned, which regimen is best for me — platinum/taxane (epithelial-leaning) or anthracycline/ifosfamide (sarcoma-leaning)?
  15. How many cycles of chemotherapy are recommended, and what is the expected benefit?
  16. What are the most common side effects of these regimens, and how are they managed?
  17. If I become resistant to platinum, what other systemic therapies could be considered?
  18. Have my tumor and blood been tested for BRCA, HRD, MSI/MMR, PD-L1, and HER2?
  19. If I have BRCA or HRD, would a PARP inhibitor be an option?
  20. If PD-L1 positive, could I qualify for immunotherapy or a clinical trial?
  21. Are there other molecular alterations (like p53, PI3K/AKT/mTOR, CLDN18.2) that could influence future treatment?
  22. Which clinical trials are available for ovarian carcinosarcoma or mixed Müllerian tumors?